Alpine Immune Sciences, Inc. (ALPN)
Stock Price:
$10.70 USD
0.06 (0.56%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
198.93M |
| Revenue (ttm) |
2.83M |
| Net Income (ttm) |
-35.00M |
| Shares Out |
23.73M |
| EPS (ttm) |
-1.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$10.70 |
| Previous Close |
$10.64 |
| Change ($) |
0.06 |
| Change (%) |
0.56% |
| Day's Open |
10.78 |
| Day's Range |
10.36 - 10.99 |
| Day's Volume |
40,174 |
| 52-Week Range |
2.05 - 15.00 |
More Stats
| Market Cap |
198.93M |
| Enterprise Value |
184.74M |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.73M |
| Float |
7.96M |
| EPS (basic) |
-1.89 |
| EPS (diluted) |
-1.88 |
| FCF / Share |
-1.86 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
45,190 |
| Short Ratio |
n/a |
| Short % of Float |
0.11% |
| Beta |
1.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
70.27 |
| PB Ratio |
7.76 |
| Revenue |
2.83M |
| Operating Income |
-36.44M |
| Net Income |
-35.00M |
| Free Cash Flow |
-34.57M |
| Net Cash |
14.19M |
| Net Cash / Share |
0.76 |
| Gross Margin |
-1,204.77% |
| Operating Margin |
-1,287.32% |
| Profit Margin |
-1,236.50% |
| FCF Margin |
-1,221.23% |
| ROA |
-38.95% |
| ROE |
-85.96% |
| ROIC |
-71.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$22.25*
(107.94% upside)
Low
19.0
Current: $10.70
High
27.0
Target: 22.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 1.74 | 0.71 | 1.73 | 2.95 | 0.49 | - | - | - |
| Revenue Growth | 146.81% | -59.27% | -41.32% | 499.59% | - | - | - | - |
| Gross Profit | 1.74 | 0.71 | 1.73 | 2.95 | 0.49 | - | - | - |
| Operating Income | -43.57 | -36.63 | -14.97 | -1.19 | -0.37 | -14.49 | -15.28 | -8.88 |
| Net Income | -41.85 | -36.49 | -7.78 | -1.23 | -0.37 | -14.66 | -16.20 | -9.57 |
| Shares Outstanding | 18.36 | 13.85 | 6.48 | 0.56 | 0.50 | 0.18 | 0.04 | 0.03 |
| Earnings Per Share | -2.28 | -2.63 | -1.20 | -2.18 | -0.74 | -81.08 | -418.00 | -278.80 |
| Operating Cash Flow | -35.35 | -28.42 | -16.57 | -3.80 | 4.82 | -14.45 | -14.29 | -9.52 |
| Capital Expenditures | -0.82 | -0.50 | -0.59 | -0.78 | -0.01 | - | -0.13 | -0.03 |
| Free Cash Flow | -36.17 | -28.91 | -17.16 | -4.58 | 4.81 | -14.45 | -14.42 | -9.55 |
| Cash & Equivalents | 40.65 | 52.30 | 81.37 | 11.82 | 87.25 | 27.81 | 3.60 | 0.00 |
| Total Debt | 16.36 | 4.20 | 5.03 | 0.11 | - | - | 15.34 | - |
| Net Cash / Debt | 24.30 | 48.10 | 76.34 | 11.71 | 87.25 | 27.81 | -11.75 | 0.00 |
| Assets | 54.09 | 54.87 | 85.22 | 12.60 | 87.91 | 28.54 | 4.13 | - |
| Liabilities | 24.62 | 10.28 | 6.31 | 2.52 | 4.42 | 44.30 | 17.63 | - |
| Book Value | 29.47 | 44.59 | 78.92 | -1.46 | 83.49 | -15.75 | -91.29 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Alpine Immune Sciences, Inc. |
| Country |
United States |
| Employees |
53 |
| CEO |
Mitchell H. Gold |
Stock Information
| Ticker Symbol |
ALPN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ALPN |
Description
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.